Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: chimeric antigen receptor natural killer cell therapeutics - Glycostem/Palvella Therapeutics

Next Previous
X
Search
Drug Profile

Research programme: chimeric antigen receptor natural killer cell therapeutics - Glycostem/Palvella Therapeutics

Alternative Names: CAR-NK cells based therapeutics - Glycostem/Palvella Therapeutics; CAR-NK cells therapy - Glycostem/Palvella Therapeutics; viveNKTM-Anticalin therapy

Latest Information Update: 17 Dec 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Glycostem; Pieris Pharmaceuticals
  • Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Solid tumours

Most Recent Events

  • 13 Dec 2024 Pieris Pharmaceuticals has merged with Palvella Therapeutics to form Palvella Therapeutics
  • 12 Mar 2021 Glycostem and Pieris Pharmaceuticals agree to co-promote and co-develop CAR-NK therapies in USA and the Netherlands for solid tumours
  • 12 Mar 2021 Early research in Solid tumours in USA, Netherlands (Parenteral) in March 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top